Sofinicline

Sofinicline
Clinical data
Other namesABT-894; ABT894; A-422894.0
Routes of
administration		Oral
Drug classα4β2 nicotinic acetylcholine receptor agonist
ATC code
  • None
Pharmacokinetic data
Onset of action2–4 hours (TmaxTooltip time to peak levels)
Elimination half-life4–6 hours
Identifiers
  • (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC10H11Cl2N3
Molar mass244.12 g·mol−1
3D model (JSmol)
  • C1[C@H]2CN(C[C@H]2N1)C3=CC(=C(N=C3)Cl)Cl
  • InChI=1S/C10H11Cl2N3/c11-8-1-7(3-14-10(8)12)15-4-6-2-13-9(6)5-15/h1,3,6,9,13H,2,4-5H2/t6-,9+/m0/s1
  • Key:MBQYQLWSBRANKQ-IMTBSYHQSA-N

Sofinicline (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code names ABT-894 and A-422894.0) is a nicotinic acetylcholine receptor (nAChR) agonist which was under development for the treatment of attention deficit hyperactivity disorder (ADHD), cognition disorders, and diabetic neuropathies but was never marketed. It is taken orally.

The drug acts as a highly selective full agonist of the α4β2 nicotinic acetylcholine receptor. It has been found to enhance cognition and memory in rodents. Sofinicline's affinity for the receptor is approximately 0.1 nM. The time to peak levels of sofinicline is 2 to 4 hours and its elimination half-life is 4 to 6 hours. Other pharmacokinetic data for sofinicline have also been reported. Side effects of sofinicline in humans include increased heart rate, nausea, dizziness, headache, and fatigue.

Sofinicline was under development by Abbott Laboratories and NeuroSearch. It reached phase 2 clinical trials for ADHD and neuropathic pain and the preclinical research stage of development for cognition disorders prior to the discontinuation of its development.

See also

References

  1. 1 2 3 4 5 "Sofinicline". AdisInsight. 23 January 2013. Retrieved 28 May 2026.
  2. 1 2 3 4 5 6 7 8 9 10 11 Fleisher C, McGough J (August 2014). "Sofinicline: a novel nicotinic acetylcholine receptor agonist in the treatment of attention-deficit/hyperactivity disorder". Expert Opinion on Investigational Drugs. 23 (8): 1157–1163. doi:10.1517/13543784.2014.934806. PMID 24965900.
  3. 1 2 3 "Delving into the Latest Updates on Sofinicline with Synapse". Synapse. 16 May 2026. Retrieved 28 May 2026.